BTIG Maintains Buy on Denali Therapeutics, Raises Price Target to $36
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Thomas Shrader maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $36.
BTIG analyst Thomas Shrader maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $36.